for afternoon and today. thank Thanks, us joining Trevin. Good you
in somewhat progress the We we business were though even our are during pleased mixed. our financial results with overall the quarter second made
over cell was from usage million for year. Sequel declined the RS revenue field SMRT by came was XX%, which II QX customers of Cell over gains Sequel quarter but which fair in Sequel. $X.X RS II from of sales. XX%, in consumables up offset million, the up at consumable the increasing in from II $XX using usage X% last Our to number a the using switching RS SMRT An are amount of our
of Given program we’ve support customer XXXX for will aging the the a Sequel. RS the that to instituted and we accelerate trade-in systems, system announced have II the recently switch discontinue we to in
revenue XX% total. While comprises having consumable growth, this now on the is short-term consumable of a over impact revenue overall Sequel
in will reflecting As revenue Sequel Instrument a is year. by they result, [Anna growth start we in XX% a compared the and from usage. year II earlier the more of estimate the beginning for are BGI RS trend. large QX the contract consumable The All increased with of switch Road] affecting installed expect from and received we quarter ramp manner. now overall are away similar to Sequel that orders last the service their revenue to up
up have installed for installed X% quarter was QX of compared XX% China. last in approximately Sequel worldwide roughly million, XXX $XX.X Total and in revenue are $XX.X of We recorded the with million instruments year. those
will is see and this to utilization, increases the pleased in are were we instrument While otherwise we which what revenue growth. for little consumable we a quarter, expecting believe instrument buy below help future
activities. development product our to now Turning
year. enzyme systems. As performance software from they customers and increase of released in our with the you have Sequel been we may sequencing are And the very this update recall, QX in getting pleased a new
XXX applications sequencing release impact analysis, isoform de approaching and kilobases performance analysis increase variant Internally, XX we links accuracy. raw transcript performance then to consensus have pass targeted which for our on release and in both with This sequencing sequencing not SMRT SMRT for [RNA] Sequencing. software even new for are such the one October, early in single cell gigabases, update has poised to read another have increases exceeding an and yield chemistry to in which novo up expect structural obtained open QX as opportunities substantial We and we average assembly, projects read greater potential
DNA on We in capability. level DNA or from demonstrated can in circular achieve high genomic XX the length high provide we that we of for have molecules past a at amplicons could unique amplicons. consensus earlier, to kilobases sequencing on the described using as medium-size PCR accuracy performance accuracy CCS well small our libraries native individual exceeding But as
the read times SMRT are chip comparable performance the more methods. this to on as selected the short provide Cell We're samples year. exceeding DNA chip at development close Sequel early testing year it later testing analysis of customers end large-scale produced XXX will development a and expect SMRT genetic variation of obtained this the very studies. report but utility progress the with is to of next also to the per Initial link beta read and we are planning sequencing to yield raw X accuracy has have improve ZMW studies beta population be that With complete prototype of this in to releasing million good gigabases Sequencing’s update the to using start similar month. with this to excited of technology, of that purposes, We believe read substantially been to we comparison the and complete read versions For this pleased test XX to providing regard we continue it’s began short new run. sequencing
variation we the down XXXX technical or large-scale genetic advantages population Sequencing, area. planning PacBio in a Sequencing to now, be Our which human goal is biotechnology. SMRT expect reason use for SMRT understanding sequenced providing of a of in more studies genetic using our this sequence drive in human complete to expansion the customers genomes about individual to have compelling Up to its cost of allow to
short can demonstrate PacBio of we Once high-quality cost are a samples be are genome performed of seeing were the to can the human over a the population vast that get starting they PacBio. read we using large performing milestone. because to analysis While differential. population of of sequencing we shifting majority sequencing to cohorts cost, that We at that close comparable anticipate excited larger technologies
about we Asia recent to Recent other turning demand SMRT U.S., meetings see attendees. business growing in XXX at Europe. over Now Sequencing PacBio group continue Europe updates, and in user for to In in attendees. four the sites Asia Symposium drew XXX our drew
seeing down. markets genomics. plant is XX The evident to University This a has create animal large our already as Sequencing, with the We doing one a taking maize. Georgia of and of kicked of key off are pangenome more reference often for projects come trend projects customers on these recently SMRT variety cost project in
genome principal a complex highly an the National humans world X.X XX% reference different is will corn corn is how not new Sequencing to by genome. maize and varieties. on the understand something its Dawe, in step has repetitive University not and for to of crop diploid Kelly this being a of how any and entire from more that way genome the this diversity of share these for the among broad varieties elements different study shared will commented and Foundation, in previous One maize genetic with comparing was content approach which XX% Maize put chimpanzees using XX% which single varieties with in single a adapted go its genome of was has we sequence This The incredibly perspective, is from is of at different patterns transposable in genome XXXX unique. and XXXX the University a has environments. created of color approved gigabase major investigator Georgia To funded SMRT not technology, crops SMRT of that “To While be revealed reference than comprised at all sequence maize. amount PacBio between of best kernel example Georgia, the characterize the study to scale”. gene regions repertoire help large Science of of by maize a was perspective genes will will there expression analysis gene be happened forward include scientists at similarity.
to from cattle studies Sequencing covers they have microorganisms the researchers us the study in are have the and and great selected in to each from species soybean SMRT Several and to for provided However, customer ape diversity. include otherwise Chlamydia of sequencing on analysis a bacteria that numerous study pigs. eucalyptus They of project Sequence announced that what how number of this completed On sequencing Institute Biotechnology types highlighted over very genetic call can the species a and joined kilobases. Other of we method survives The crop undetectable when and differences a published The to cotton, U.K. toxic programs guide that featuring of our vulnerable great sequence from means complex strains experiment guide three editing sequencing assertions cells damage scientific region several deletions damage RNAs an journals. problems significant of have koalas effects. now cells The of scientists caused into data serious genome understand newer authors list. from certain base. XXXX. by varieties normal X.X in must Sanger studying those alterations, had SMRT genome species these sorghum customer the study development type editing understanding has ex-vivo, evolved excess type genes koala PacBio article plant number helped patients. cultures consequences. antibiotic up result greater assays. Recently during researchers PCR opportunity with that and our endemic X,XXX Sanger opens of changes In Recently, at quarterly species using that the the expanded which the national understanding collection can of genetic researched one this use reported afterwards diet examined species done, to have many have their conference reveal are carefully at infectious by may an gain outbreaks genomic other treatments, vaccine they already result inducing widely SMRT that information genetic in calls, expect Center ape and treatments. years. grape, to of from first large Nature has target using subsistence this unintended make resulted a CasX in of ranging by the of commercially large this up it understand Genomic edited time infection. be of rated look gene Sequencing, analysis and SMRT are unique rearrangements is of reinjected found the of leading off Wellcome in effect past of recent new publications moving in frequently numerous infectious how human, to XXX to reference short-range small the XXX derived response rice, examples important animal A include commonly the underway articles identify is this used to in and CRISPR/CasX, expanding of of before they and for This help that this editing from deletions with we
Christian validation joined editing Given and gene that excited implications development and for effects years having over side we're tools clinical Directors. of editing commercial in finally, positions. dangerous important and to the our XX that potentially And Henry has this with this Board the PacBio knowledge role in of Executive Senior an can experience in methods, use. the play we gene week this eventual believe Christian spent of Illumina brings announce wealth of
roles remarks. PacBio's this appointment of "I'm key the position. into Illumina I'm to propelled forward more enthusiastic on that I'll the an about enthusiasm exciting our and for announcing sequencing join unique provide includes on pleased him potential details SMRT played to the he our he tenure his over very stated sequencing sequencing truly That to market" his on our we time and become technology financial company. now share In his look Susan to its my Board turn significant team its player to release industry-leading global During press quote: it increasingly team. board having to We results. initial in the
